In the preceding three months, 7 analysts have released ratings for BioMarin Pharmaceutical (NASDAQ:BMRN), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 2 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $81.71, along with a high estimate of $100.00 and a low estimate of $60.00. Experiencing a 3.22% decline, the current average is now lower than the previous average price target of $84.43.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive BioMarin Pharmaceutical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leland Gershell | Oppenheimer | Lowers | Outperform | $95.00 | $98.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $75.00 | $70.00 |
| Allison Bratzel | Piper Sandler | Lowers | Overweight | $84.00 | $122.00 |
| Whitney Ijem | Canaccord Genuity | Raises | Buy | $98.00 | $84.00 |
| Joon Lee | Truist Securities | Raises | Buy | $100.00 | $80.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Raises | Neutral | $60.00 | $55.00 |
| Joseph Schwartz | Leerink Partners | Lowers | Market Perform | $60.00 | $82.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BioMarin Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioMarin Pharmaceutical compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of BioMarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into BioMarin Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on BioMarin Pharmaceutical analyst ratings.
Get to Know BioMarin Pharmaceutical Better
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
BioMarin Pharmaceutical's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining BioMarin Pharmaceutical's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.08% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BioMarin Pharmaceutical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.51%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: BioMarin Pharmaceutical's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
- No comments yet. Be the first to comment!